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Summary
Background.— Both French and international guidelines recommend long-term use of
betablockers, antiplatelet drugs, statins, angiotensin-converting enzyme inhibitors or
angiotensin-receptor blockers (ACE-I/ARB) after a myocardial infarction (MI), but data on their
combined use are scarce in France.
Aims.— To evaluate the use of combined medication 6months after hospital admission for MI
and the factors that can signiﬁcantly inﬂuence their use.
Methods.— All hospital admissions for MI in France from January to June 2006 were selected
from the national hospital discharge database. Data on medications used 6months before and
after hospitalization for patients covered by the general health insurance scheme (70% of French
population) were collected from the reimbursement information system. A medication was
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ment satisfaisant. Les recommandations doivent être encore diffusées vers les professionnels
non cardiologues et précisées pour des sous-groupes comme les malades de 75 ans et plus ou
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n 2005, there were 40 597 deaths from ischaemic heart dis-
ase among the 62.4 million inhabitants in France, i.e. 7.7%
f all deaths and one of the lowest rates in Europe [1].
he three French registers of acute coronary syndromes,
btained from the Multinational Monitoring of trends and
eterminants in Cardiovascular disease (MONICA) Project,
bserved an overall reduction in mortality between 1992 and
002, particularly hospital fatality, but not in the incidence
f coronary disease. This improvement can be explained
artly by the increase and improvement in recommended
nvasive and non-invasive treatments [2,3].
In 2007, the French National Authority for Health
HAS) published guidelines for coronary disease man-
gement. As in many international recommendations on
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econdary prevention for patients with a myocardial infarc-
ion (MI), recommended medications include a combination
f betablockers, aspirin and/or clopidogrel, statins and
ngiotensin-converting enzyme inhibitors (ACE-I), which
ay be replaced by an angiotensin-receptor-blocker (ARB)
4].
These recommendations are based on the results of
tudies that observed decreased rates of cardiovascular
eath and serious cardiac events, as well as an advanta-
eous cost-effectiveness ratio for each class of medications
nd their combination [5]. ‘Real-world’ studies in North
merica and Europe have observed a temporal increase in280 P. Tuppin et al.
considered to be used when there were more than three reimbursement applications over the
6months following the index episode. Comorbidities were ascertained from the use of disease-
speciﬁc medication reimbursements and registration in the national database of full coverage
for 30 long-term disorders.
Results.— Of the 11 671 patients included, 82% were reimbursed for betablockers, 92% for
antiplatelets, 85% for statins, 80% for ACE-I/ARBs and 62% for all four classes. After adjustment,
signiﬁcant underuse was found for women, the elderly and those with several comorbidities.
Treatment at a university hospital or high-volume centre, follow-up by a cardiologist and use of
revascularization procedures were associated with improved rates of combination therapy use.
Conclusion.— Overall, use of recommended medications after MI in France is satisfactory,
though not optimal. Speciﬁc recommendations focusing on subgroups such as older patients or
those with comorbidities, as well as information directed towards non-specialized healthcare
professionals, should help to improve appropriate use of these medications.
© 2009 Published by Elsevier Masson SAS.
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Résumé
Introduction.— La prévention secondaire médicamenteuse recommandée après un infarctus
du myocarde (IM) est l’association bêtabloquant, statine, antiagrégant plaquettaire (AP) et un
inhibiteur du système rénine-angiotensine (ACE-I/ARB), mais peu de données sont disponibles
en France.
Objectif.— Évaluer l’utilisation de cette association après hospitalisation et les facteurs asso-
ciés.
Méthodes.— La base nationale des séjours hospitaliers a fourni les hospitalisations pour un IM
au premier semestre 2006. Elle a été complétée par celle des remboursements médicaux du
régime général de l’assurance maladie six mois avant et après l’hospitalisation. La consomma-
tion d’un médicament a été retenue par la présence d’au moins trois remboursements pendant
les six mois suivant l’hospitalisation. Des comorbidités ont été déﬁnies par le remboursement
de médicaments traceurs ou l’existence d’une affection de longue durée (ALD).
Résultats.— Parmi les 11 671 patients inclus, 82 % ont été remboursés pour un bêtabloquant,
92 % pour un AP, 85 % pour une statine, 79 % pour un ACE-I/ARB et 62% pour l’association.
Après ajustement, l’association est signiﬁcativement moins utilisée chez les femmes, les
malades âgés, ceux avec une insufﬁsance rénale, une maladie respiratoire obstructive, une
maladie d’Alzheimer ou de Parkinson. L’utilisation est plus élevée avec la spécialisation
de la prise en charge : établissement universitaire ou volume élevé d’hospitalisations pour
IM dans l’établissement, réalisation d’un pontage ou stent coronaire avant, pendant ou
après l’hospitalisation index, consultation d’un cardiologue en libéral après l’hospitalisation,
présence d’un diabète et d’une ALD cardiovasculaire.
Conclusion.— Le niveau d’utilisation des médicaments de la prévention secondaire est globale-he use of secondary prevention therapy, although several
haracteristics were associated with a lower use of rec-
mmended medications (e.g., certain geographical regions,
lder age, female sex, presence of comorbid conditions
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use of individual and combined secondary prevention med-
ications. Combination therapy was adjusted for sex andCombined secondary prevention after hospitalization for my
or associated treatments, lower level of social protection,
management at non-university hospitals, lack of follow-
up by a cardiologist, or coronary artery bypass surgery)
[6—24]. These studies were conducted on the basis of hospi-
tal data or of registers with populations of various sizes,
but rarely nationwide. In France, a register of approxi-
mately 1700 patients recruited by a representative group
of cardiologists reported a prescription level of 46.2%
upon hospital discharge in 2006 for the selected combi-
nation of treatments, without taking into account ARBs
[25].
The objective of this study was to assess the level of use
of medications recommended for secondary prevention, and
of their combination, after hospitalization for MI in France,
as well as the factors correlated with their use.
Methods
In France, the general health insurance scheme covers 70%
of the population, i.e. 48 million people in 2006. Its informa-
tion system (SNIIRAM) contains individualized, anonymous
and exhaustive data on all health spending reimbursements.
Other information is also recorded, such as the existence of
universal healthcare coverage for low earners (CMUC) or for
people suffering from one of 30 long-term disorders (LTDs)
that entitle patients to full reimbursement. This information
was linked to the French hospital discharge database, which
is used for hospital payment and provides medical informa-
tion for all patients discharged from both private and public
hospitals.
Study population
All hospitalizations from January to June 2006 with a
diagnosis-related group of MI (05K05V, 05K05W, 05M02E,
05M03Z, 05M04V, 05M04W and 24Z09E) were selected
from the programme de médicalisation des sytèmes
d’information (PMSI) data on short-term hospital stays.
We selected patients who were covered by the general
scheme and the ﬁrst hospital admission for MI was selected
as the index hospital admission. They were then linked,
using a common, anonymous patient number, to the corre-
sponding records in the reimbursement database. Contact
with patients who received no treatment reimbursement
four to six months after the index hospital admission was
considered lost and were excluded. Possible reasons for lost
contact include death after hospital admission, relocation
abroad, change in social security number (e.g., widowed
women) and treatment in a follow-up and rehabilitative
care establishment after hospital discharge.
Variables studied
For each index hospital admission, the following were
selected: diagnosis-related group, coronary stent implant
procedure (coded according to the classiﬁcation of medical
procedures used in France: DDAF003, DDAF004, DDAF006-
DDAF009), sex, age, length of stay and, for healthcare
establishments, type of hospital and activity volume (num-
ber of admissions with a discharge diagnosis of MI in each
establishment during 2006).
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Consumption of a major class of medications (antihyper-
ensive, antiplatelet, antidiabetic, anti-inﬂammatory and
ipid-lowering drugs, oral anticoagulants, cardiotonic glyco-
ides, class III antiarrhythmic agents, nitrates, vasodilators)
as considered to be ‘regular’ after at least three medi-
ation deliveries per patient per six-month period (before
nd after the index hospital admission). No limit was set for
eparins.
Cardiovascular morbidity (coronary artery disease: acute
yocardial infarction, angina pectoris, coronary atheroscle-
osis; coronary artery bypass surgery; stent implantation
rocedures) was identiﬁed using speciﬁc diagnosis-related
roups notiﬁed during hospital stays, six months before
nd after the index hospital admission. Hospitalizations for
on-cardiovascular reasons (other diagnosis-related groups)
ere grouped into hospital stays ‘other than cardiol-
gy’. Comorbid conditions were deﬁned in several ways:
atients with Alzheimer’s disease, Parkinson’s disease or
epression were identiﬁed through reimbursements of spe-
iﬁc treatments issued at least three times over the six
onths before the index hospital admission. For kidney
ailure, LTD patients with ‘chronic kidney failure’ and/or
reated with dialysis were selected. Obstructive respira-
ory diseases were characterized by the reimbursement
f indicator medications at least twice over the pre-
ious six months. Diabetic patients were identiﬁed by
he speciﬁc LTD and/or three reimbursements of speciﬁc
reatments over the six months before or after hospital-
zation. For malignant tumours, the following indicators
ere used: radiotherapy and chemotherapy sessions or
ospital admission with a main diagnosis of cancer, or spe-
iﬁc cancer LTD declared within the past two years. For
sychiatric disorders and chronic liver disease, only the
peciﬁc LTD was used. Appointments with a private car-
iologist over the six months before and following the
ndex hospital admission were recorded when there was
t least one reimbursement for each of these periods.
o study the impact of full reimbursement of medica-
ions, the speciﬁc LTDs for cardiovascular disease were also
ecorded.
tatistical analysis
nivariate and bivariate analyses were conducted to
escribe the patients included and to compare the rates
edication use according to their baseline characteristics
nd treatments used before and after the index hospi-
al admission (Kruskal-Wallis tests for continuous variables
nd the chi2 test for discrete variables). For each recom-
ended class of medication and for their combined use,
he crude odds ratios (OR) with their 95% conﬁdence inter-
als (CIs) were calculated. Multivariable logistic regression
nalysis was used to test independent correlates of thege. An overall adjustment was used for each individ-
al class of medications. A p value less than 0.05 was
onsidered to be statistically signiﬁcant. The data were
nalysed using SAS software (SAS version 9.1.3, SAS Inc, Cary,
C).
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esults
opulation and treatment
n the ﬁrst half of 2006, 24 075 hospital stays had an
I diagnosis-related group. The anonymous patient num-
er was missing for 1707 (7.1%) of these and, of the
2 374 remaining, only 14 788 (66.1%) hospital admissions
oncerned 14,007 patients covered by the general health
nsurance scheme. As speciﬁed in the methods section,
atients who died in hospital (n = 1354, 9.7%) were excluded,
s well as the other 982 (7.0%) lost contacts after the hospi-
al stay. The study focused on the remaining 11 671 patients,
hose baseline characteristics and treatments are described
n Table 1.
Of those, 69.7% of patients were men (mean age
1.4± 13.6 years) and 30.3% women (mean age 72.6± 14.0
ears). Men and younger patients were more often hos-
italized in university hospitals or private clinics, and in
entres with a high MI activity volume. During the index hos-
italization, 57.2% of patients had a percutaneous coronary
ntervention (PCI) with implantation of at least one stent.
During the six months prior to hospital admission for MI,
4.4% of patients had consulted a private cardiologist, 10.9%
ad been hospitalized for cardiovascular causes including
.8% with a stent implantation. In the six months follow-
ng the index hospitalization, 46.3% consulted a private
ardiologist and 45.3% had a further hospital record for
ardiovascular causes, 15.6% with a stent implantation and
.4% for coronary artery bypass surgery. The most common
omorbidities were diabetes (21.4%), illnesses treated with
nti-inﬂammatory medications (13.8%), depression (8.9%),
bstructive pulmonary disease (8.4%) and cancer (4.7%). The
roportion of patients with a registered LTD for coronary
isease increased from 11.4 to 63.3% after hospitalization,
hile the proportion of other cardiovascular LTDs was more
table (12.7 to 18.3%). At six months, 11.0% of the patients
ad no administrative record of any LTD.
edications reimbursed
able 2 reports the use of the four classes of medica-
ions according to the patients’ baseline characteristics.
efore index hospitalization for MI, the use of each of the
our groups was around 25%, except ACE-I/ARB (34%), with
% taking a combination of these four classes. After hos-
italization, reimbursed prescription rates rose to 82.4%
or betablockers, 92.0% for antiplatelet agents, 85.4% for
tatins and 79.5% for ACE-I/ARB; 62.1% of patients were on
combination of these treatments. Regarding antiplatelet
gents, 79.9% of patients received clopidogrel, 84% aspirin
nd 72% both.
orrelates of use of recommended
edications
actors associated with the use of recommended medica-
ions are reported in Tables 3 and 4. Men were more likely
han women to take antiplatelet agents or combination
reatment. Age had a signiﬁcant effect, especially on the
onsumption of statins and ACE-I/ARBs, with fewer younger
r older patients using these medications. Consumption of
5
s
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etablockers was signiﬁcantly lower in patients more than or
qual to 75 years and that of antiplatelet agents was lower
n those more than or equal to 85 years. Combined therapy
as much less frequently used in patients aged more than
r equal to 75.
Consumption of betablockers, statins, ACE-I/ARBs and
ombination therapy was more frequent after admission to
university hospital. Admission to high MI volume hospitals
as positively correlated with the use of statins, ACE-I/ARBs
nd combined treatment. Consumption of each of the four
lasses and their combination was higher when the patients
ad had at least one visit to a private cardiologist.
Stent implantation, during and after the index hospital
dmission, was positively and signiﬁcantly associated with
osthospitalization use of each of the classes and of their
ombination. Readmission to hospital for coronary disease
ncreased consumption of combined therapy.
Overall, comorbidities (cancer, kidney failure, Parkin-
on’s disease and Alzheimer’s disease, etc.) had a negative
nﬂuence on the use of recommended medications. Dia-
etes, however, was associated with a higher consumption
f each class and of their combination.
A positive correlation was observed between the use of
iuretics and that of ACE-I/ARBs or betablockers. Use of
alcium-channel blockers was negatively associated with
ombined therapy, betablockers and ACE-I/ARBs, and was
ositively associated with antiplatelet agents and statins.
everal other medications were negatively linked to class III
ntiarrhythmics and betablockers, ﬁbrates and statins, oral
nticoagulants and antiplatelet agents.
iscussion
his study, which combined hospitalization and reimburse-
ent data for 11,671 patients admitted for MI in the ﬁrst half
f 2006, is the ﬁrst to use such a methodology in this medical
ontext in France. The data show that 62% of patients take
he recommended quadruple therapy over the six months
ollowing hospitalization for an MI.
omparisons with international and French
ata
ompared with international data, the level of use of
ombined therapy and of each class of medications appears
igh in France, especially for statins and antiplatelet agents
6—12,22—24]. Comparisons between studies are limited by
he variation of inclusion criteria, the techniques used to
easure consumption of medications, patients case-mix,
he year of study, and developments in professional practice
ecommendations and health coverage systems. In indus-
rialized countries, a regular increase in the prescription
f recommended medications has been observed since the
nd of the 1990s [6—10]. The current data represent a
ajor improvement compared with data reported in France
n 2000 from a register of 2119 patients, which recorded
2% use of combined betablockers, antiplatelet agents and
tatins, and a 27% prescription of quadruple combination
herapy at hospital discharge [26]. At the end of 2004, in a
egister of 2443 patients followed-up by cardiologists after
n acute coronary syndrome, 94.8% were taking aspirin,
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Table 1 Characteristics of the 11,671 patients admitted for myocardial infarction in France during the ﬁrst half of 2006.
Age (years) Sex Total
< 45 45—54 55—64 65—74 75—84 > 84 p Female Male p
N 1045 2225 2394 2470 2570 967 3534 8137 11671
Mean age (years) 39.3 49.8 59.2 69.8 79.3 88.7 72.6 61.4 ∗ ∗ ∗ 64.8
Men 85.6 85.7 82.8 70.1 51.3 31.4 *** — — 69.7
Full healthcare coverage for low earners 14.8 11.9 8.0 2.1 0.9 0.6 *** 5.0 6.3 ∗∗ 5.9
Six months before hospitalization
One or more outpatient cardiologist appointments 5.4 8.5 12.4 17.9 20.5 16.9 *** 15.4 13.9 * 14.4
Admitted to cardiology unit for: *** ***
Stent implantation 1.9 2.5 2.7 3.8 3.1 1.1 2.7 2.8 2.8
Other diagnoses 3.6 5.1 7.1 8.9 10.9 12.5 9.8 7.3 8.1
Admitted to another unit 12.8 12.3 14.2 19.7 23.1 23.2 *** 20.9 16.1 *** 17.6
Hospitalization for MI
Hospital type *** ***
University hospital 41.1 39.5 33.1 30.9 25.9 20.8 27.8 33.8 32.0
Private clinic 21.5 22.9 25.4 23.7 20.9 16.6 19.6 23.7 22.5
Community hospital 37.4 37.7 41.5 45.4 53.3 62.6 52.7 42.5 45.6
Annual MI admitted to hospital (2006) *** ***
≤ 49 4.4 5.2 5.7 9.0 12.0 20.4 11.5 7.6 8.8
50—99 9.5 12.9 14.5 15.9 20.0 22.2 18.6 14.7 15.9
100—299 39.5 38.2 39.0 38.5 36.2 32.9 36.9 38.0 37.6
≥ 300 46.6 43.7 40.8 36.6 31.8 24.5 33.1 39.7 37.7
Stent implantation 68.9 72.1 65.6 58.1 45.2 18.7 *** 43.0 63.3 *** 57.2
Length of stay (weeks) *** ***
≤ 1 77.5 77.7 73.6 64.0 49.8 37.2 51.7 70.0 64.4
2 18.7 18.6 21.5 27.6 35.4 42.6 34.2 23.6 26.8
3 2.7 2.4 3.0 5.3 9.4 13.1 9.1 4.1 5.6
≥ 4 1.1 1.3 1.9 3.1 5.4 7.0 5.0 2.4 3.2
Six months after hospitalization
Admitted to cardiology unit for: *** ***
Stent implantation 12.5 15.6 17.3 18.2 16.2 6.3 12.6 16.9 15.6
Coronary bypass graft 1.1 2.6 4.9 5.2 2.7 0.4 2.0 3.9 3.4
Coronary disease 9.4 8.2 8.4 11.5 11.9 11.9 11.8 9.5 10.2
Catheterization 7.5 6.4 6.4 5.7 5.2 1.2 5.6 5.7 5.6
Other diagnosis 10.1 9.8 8.4 9.2 12.2 16.5 12.5 9.7 10.5
Admitted to another unit 23.5 23.6 26.1 31.4 34.0 34.6 *** 32.3 27.5 *** 29.0
One or more outpatient cardiologist appointments 43.8 48.1 49.0 49.6 45.9 30.6 *** 42.8 47.8 *** 46.3
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Table 1 (Continued )
Age (years) Sex Total
< 45 45—54 55—64 65—74 75—84 > 84 p Female Male p
Associated medications
Non-thiazide 9.2 12.9 18.7 32.6 49.5 64.6 *** 43.7 24.4 *** 30.3
Thiazide 3.1 4.6 8.3 11.9 11.6 7.4 *** 11.3 7.3 *** 8.5
Calcium-channel blocker 12.4 12.8 18.3 23.2 24.4 25.3 *** 22.9 18.3 *** 19.7
Cardiotonic steroid 0.2 0.3 1.3 2.3 3.6 *** 2.2 0.8 *** 1.2
Antiarrhythmia agent class III 1.0 1.4 3.7 7.6 12.6 14.7 *** 9.2 5.7 *** 6.7
Nitrate 7.1 7.5 9.1 11.9 19.1 32.3 *** 18.9 10.9 *** 13.3
Vasorelaxant 6.1 6.9 9.6 11.9 15.8 21.2 *** 14.1 10.5 *** 11.6
Fibrate 1.3 1.7 1.5 1.3 1.6 0.8 *** 1.4 1.5 *** 1.4
Non-statin and ﬁbrate lipid-lowering drugs 21.7 20.4 16.7 11.5 6.3 2.2 *** 9.3 15.0 *** 13.3
Heparin 3.2 4.3 5.4 8.1 8.0 6.6 *** 6.5 6.1 *** 6.2
Oral anticoagulant 3.3 3.1 5.0 8.7 11.9 10.8 *** 9.0 6.5 *** 7.3
Comorbidity
Neoplasia 1.1 1.8 5.0 6.1 6.5 6.2 *** 3.9 5.0 ** 4.7
Diabetes mellitus 7.0 13.6 22.4 29.1 26.4 19.2 *** 26.1 19.3 *** 21.4
Renal disease 0.4 0.6 0.8 1.2 2.3 0.6 *** 1.3 1.0 1.1
Chronic obstructive pulmonary disease 4.4 5.8 7.1 9.4 11.8 10.3 *** 9.0 8.2 8.4
Alzheimer’s disease 0.0 0.0 0.0 0.5 1.6 2.2 *** 1.2 0.4 *** 0.7
Parkinson’s disease 0.0 0.0 0.1 0.7 1.8 1.8 *** 1.2 0.5 *** 0.7
Depression 5.4 6.6 6.8 7.7 12.1 17.3 *** 15.1 6.2 *** 8.9
Non-steroidal anti-inﬂammatory use 8.4 10.3 12.2 16.7 17.4 14.8 *** 19.2 11.5 *** 13.8
Chronic hepatic disease 1.0 0.6 0.5 0.6 0.2 0.1 * 0.3 0.6 0.5
Psychotic disorder 3.5 3.6 2.6 1.7 2.2 1.6 *** 3.1 2.2 ** 2.5
Full coverage for LTD
LTD for coronary disease *** ***
Before MI hospitalization 6.5 8.4 10.1 12.6 14.0 16.6 8.9 12.5 11.4
After MI hospitalization 71.8 70.6 60.6 47.6 34.2 24.2 42.2 56.1 51.9
LTD for other cardiological disease *** ***
Before MI hospitalization 2.1 5.3 8.9 14.9 20.6 23.8 17.6 10.6 12.7
After MI hospitalization 3.3 4.5 6.0 6.2 6.5 5.7 6.8 5.1 5.6
No LTD 13.6 9.7 9.9 9.5 11.6 15.9 *** 12.4 10.4 ** 11.0
*< 0.05, **< 0.01, ***< 0.001.
Data expressed as a percentage unless otherwise stated. LTD: long-term disorder; MI: myocardial infarction.
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Table 2 Evidence-based treatment frequency in the 6 months after myocardial infarction in France during the ﬁrst half
of 2006 according to patients’ characteristics and medication.
Betablocker Antiplatelet Statin ACE-I/ARB Combination
Whole study population 82.4 92.0 85.4 79.5 62.1
Men 84.7 94.0 89.3 80.6 66.6
Age
≤ 44 years 87.5 94.0 90.1 75.7 67.8
45—54 90.3 96.7 94.4 81.1 73.6
55—64 87.8 94.9 92.4 81.7 70.6
65—74 84.0 93.3 90.1 84.0 67.2
75—84 75.6 88.4 79.6 78.1 50.6
≥ 85 58.8 78.5 45.8 66.2 25.7
Full healthcare coverage for low earners 85.7 93.2 87.6 78.4 64.5
Six months prior to hospitalization
One or more outpatient cardiologist appointments 80.0 90.9 83.8 80.3 58.1
Admitted to cardiology unit for:
Stent implantation 82.5 94.5 89.8 84.9 67.4
Other diagnoses 77.0 86.6 77.4 76.2 49.4
Admitted to other unit 76.8 88.2 78.5 76.1 53.3
Hospitalization for MI
Hospital type
University hospital 86.4 92.7 89.9 84.9 71.7
Private clinic 83.6 95.3 88.4 76.3 60.7
Community hospital 79.0 89.9 80.8 77.2 56.0
Annual MI admitted to hospital (2006)
≤ 49 72.3 87.2 71.0 73.4 45.7
50—99 77.8 90.4 79.5 73.9 52.6
100—299 83.6 92.5 87.4 79.1 62.7
≥ 300 85.4 93.4 89.3 83.6 69.3
Stent implantation 88.4 97.6 93.7 83.3 72.2
Length of stay (weeks)
≤ 1 85.6 94.1 89.5 79.9 66.4
2 79.3 90.6 81.4 80.1 57.9
3 70.3 84.6 71.9 77.1 46.8
≥ 4 65.0 75.3 61.0 69.4 35.8
Six months after hospitalization
Admitted to cardiology unit for
Stent implantation 88.4 98.0 93.3 83.0 71.2
Coronary bypass grafting 86.2 89.8 91.8 83.9 67.3
Coronary disease 83.1 91.2 81.8 83.0 63.7
Catheterization 81.6 91.8 87.1 78.8 59.5
Other diagnosis 77.8 87.6 80.4 78.4 54.5
Admitted to other unit 78.9 89.4 80.2 78.1 56.8
One or more outpatient cardiologist appointments 86.1 95.7 90.6 82.2 66.4
Associated medications
Non-thiazide 78.2 89.3 77.3 85.6 55.3
Thiazide 82.6 92.6 88.5 95.0 68.9
Calcium channel blocker 64.7 93.1 84.5 78.0 45.9
Cardiotonic steroid 62.3 71.7 58.7 85.5 33.3
Antiarrhythmia agent class III 63.9 84.9 73.2 79.6 39.4
Nitrate 77.2 91.8 79.0 77.9 52.5
Vasorelaxant 77.9 93.4 82.4 77.9 54.7
Fibrate 80.8 92.8 67.1 76.0 48.5
Non-statin and ﬁbrate lipid-lowering drugs 91.8 98.4 97.3 87.9 78.9
Heparin 79.4 87.2 82.3 80.6 53.7
Oral anticoagulant 77.4 67.3 79.7 82.2 44.8
Comorbidity
Neoplasia 76.4 87.8 78.2 75.0 50.6
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Table 2 (Continued )
Betablocker Antiplatelet Statin ACE-I/ARB Combination
Diabetes mellitus 81.5 91.9 84.2 86.2 63.7
Renal disease 80.2 88.5 74.8 56.5 38.2
Chronic obstructive pulmonary disease 55.2 91.6 80.5 80.9 41.3
Alzheimer’s disease 59.2 84.2 53.9 73.7 26.3
Parkinson’s disease 66.7 86.9 60.7 65.5 31.0
Depression 78.6 89.5 78.2 76.9 52.7
Non-steroidal anti-inﬂammatory use 80.3 92.7 84.5 81.4 59.3
Chronic hepatic disease 77.6 86.2 82.8 70.7 55.2
Psychotic disorder 75.1 86.7 77.8 71.0 52.2
Full coverage for a LTD
LTD for coronary disease
Before MI hospitalization 80.3 91.9 84.0 80.1 58.5
After MI hospitalization 89.9 97.3 93.8 82.5 71.7
LTD for other cardiological disease
Before MI hospitalization 74.2 86.9 77.1 79.5 50.9
After MI hospitalization 81.7 89.8 84.1 84.9 62.5
No LTD 70.5 80.3 70.5 67.7 48.2
ACE: angiotensin-converting enzyme; LDT: long-term disorder; MI: myocardial infarction.
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0% statins, 85% thienopyridines, 79% betablockers, 47.7%
CE-I and 13.3% ARBs/sartan upon discharge from hospital
or MI [27]. In another survey of 1700 patients, carried
ut in 2006, the proportion receiving quadruple therapy
excluding ARBs) was 46% [25]. These proportions may
ave been overestimated, as they were observed only for
atients who consulted a cardiologist.
orrelates of use of recommended
edications
se of combination therapy should be limited mainly by
bsolute, and possibly relative, contraindications, or by
ntolerance to the medications. In theory, more than 95%
f patients may be treated by statins, as true contraindi-
ations are rare. The same applies for ACE-I/ARBs, whereas
ontraindications are more common for betablockers. These
ere taken by 82% of patients, but higher levels at 90%
ave been reported in selected centres, such as was the
ase in the Global Registry of Acute Coronary Events
GRACE) [9].
Health coverage policies are likely to have an impact
n medication consumption. The positive effect of ﬁnan-
ial reimbursement on prevention or care consumption has
lready been widely documented. In this regard, it is encour-
ging to note that patients receiving total reimbursement
or treatment expenses (CMUC), have similar levels of use
f recommended medications, in spite of their lower socioe-
onomic status.
The lower prescription of secondary prevention treat-
ents in women is a concern. In this study, however, theower rates observed in women disappeared after multivari-
ble adjustment for all classes except antiplatelet agents.
low prescription of clopidogrel in women has already been
eported [28,29]. A lower frequency of stent or bypass use
n women has also been reported, and is partly explained
s
a
o
y
wy their older age and by the particular anatomy of the
oronary arteries in women [29].
Older age is known to be a negative and independent fac-
or against the use of prevention treatments [11—17]. In our
tudy, the reduction in combined secondary prevention ther-
py over the age of 75 is due to the reduction in the use of
tatins and, to a lesser extent, betablockers and aspirin. The
egative effect of age remained after adjustment. Although
lder age is associated with an increase in the frequency
f cardiovascular comorbidities and possible interactions,
hich may contraindicate the prescription of secondary pre-
ention medications, it is unlikely that these factors alone
ccount for the drop in the use of secondary preventionmed-
cations in elderly patients. Although very few randomized
rials have speciﬁcally been devoted to elderly populations,
nd the proportion of elderly patients in the trials is usu-
lly extremely low, there is no evidence that the efﬁcacy of
hese medications in older patients is less. Indeed, a posi-
ive effect of betablockers and statins in patients aged 75
ears and over has been observed in terms of both survival
nd cost-effectiveness [30—32].
A paradoxical effect has been described for statins: their
ate of prescription decreases as the patient’s risk level
ncreases [33]. This may be because prescribers think that
hese patients have a substantial risk of dying before the
reventive measures have had time to take effect. Such a
ias has been reported for the use of statins in Alzheimer’s
isease and Parkinson’s disease or for psychiatric disorders
12,14]. There is no question, however, that prescribing
econdary prevention medications in patients with severe
omorbidities may represent a true ethical issue for pre-
cribers, which is beyond the scope of the present study to
ddress. At the other end of the spectrum, the lower use
f secondary prevention therapy in the very young (< 45
ears) comes as a surprise and is of interest. Compared
ith patients aged 45 to 54 years, those less than 45 have
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Table 3 Factors associated with use of each medication included in evidence-based treatment six months after myocar-
dial infarction in France.
Beta-blocker Antiplatelet Statin ACE-I/ARB
OR ORa OR ORa OR ORa OR ORa
Male sex 1.7*** 1.0 2.2*** 1.2* 2.5*** 1.1 1.2*** 1.1
Age (years)
≤ 44 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0
45—54 1.3* 1.3* 1.9*** 1.6* 1.8*** 1.7*** 1.4*** 1.3*
55—64 1.0 1.2 1.2 1.3 1.3* 1.4** 1.4*** 1.3*
65—74 0.8** 1.0 0.9 1.2 1.0 1.4* 1.7*** 1.4***
75—84 0.4*** 0.8* 0.5*** 1.0 0.4*** 0.9 1.1 1.0
≥85 0.2*** 0.4*** 0.2*** 0.7* 0.1*** 0.3*** 0.6*** 0.7***
Full healthcare coverage for low earners 1.3* 1.1 1.2 1.0 1.2 0.8 0.9 1.0
Six months prior to hospitalization
One or more outpatient cardiologist
appointments
0.8** 1.1 0.8 1.0 0.9* 1.1 1.1 1.0
Admitted to cardiology unit for
Stent implantation 1.0 1.0 1.4 1.2 1.4* 1.4 1.4* 1.4
Other diagnoses 0.7*** 1.0 0.5*** 0.8* 0.6*** 0.8* 0.8* 0.8
Admitted to other unit 0.7*** 0.9 0.6*** 0.8* 0.6*** 0.8* 0.8*** 0.9
Hospitalization for MI
Hospital type
University hospital 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0
Private clinic 0.8**** 0.7*** 1.6*** 1.2 0.9 0.7*** 0.6*** 0.5***
Community hospital 0.6*** 0.8*** 0.7*** 1.1 0.5*** 0.8** 0.6*** 0.7***
Annual MI admitted to hospital (2006)
≤ 49 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0
50—99 1.3** 1.1 1.4** 1.0 1.6*** 1.2 1.0 0.9
100—299 2.0*** 1.3* 1.8*** 0.9 2.8*** 1.5*** 1.4*** 1.1
≥ 300 2.2*** 1.2 2.1*** 1.1 3.4*** 1.4** 1.8*** 1.2*
Stent implantation 2.6*** 1.7*** 7.4*** 5.2*** 5.1*** 2.9*** 1.7*** 1.6***
Length of stay
≤ 1 week 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0
2 0.6*** 0.9 0.6*** 0.9 0.5*** 0.8* 1.0 1.0
3 0.4*** 0.7*** 0.3*** 0.8 0.3*** 0.7*** 0.8 0.8
≥ 4 0.3*** 0.5*** 0.2*** 0.4*** 0.2*** 0.4*** 0.6*** 0.5***
Six months after hospitalization
Admitted to cardiology unit for
Stent implantation 1.8*** 1.9*** 4.6*** 4.3*** 2.6*** 2.7*** 1.4*** 1.4***
Coronary bypass graft 1.4* 1.7** 0.8 1.0 2.*** 2.4*** 1.5** 1.4*
Coronary disease 1.1 1.3** 1.0 1.2 0.8* 0.9 1.4*** 1.4***
Catheterization 1.0 1.1 1.0 1.2 1.3 1.2 1.1 1.0
Other diagnosis 0.8** 1.0 0.7*** 0.9 0.8*** 1.1 1.0 0.9
Admitted to other unit 0.7*** 0.9 0.6*** 0.9 0.6*** 0.7*** 0.9* 0.9
One or more outpatient cardiologist
appointments
1.6*** 1.4*** 2.8*** 1.9*** 2.3*** 1.5*** 1.4*** 1.3***
Associated medications
Non-thiazide 0.7*** 1.6*** 0.6*** 1.8*** 0.4*** 1.1 1.8*** 3.0***
Thiazide 1.0 1.6*** 1.1 1.1 1.3** 1.4** 5.3*** 6.4***
Calcium channel blocker 0.3*** 0.3*** 1.2* 1.5*** 0.9 1.2* 0.9 0.8**
Cardiotonic steroid 0.3*** 0.7 0.2*** 0.7 0.2*** 0.6** 1.5 1.6
Antiarrhythmia agent class III 0.3*** 0.4*** 0.5*** 1.1 0.4*** 0.8 1.0 0.9
Nitrate 0.7*** 1.2* 1.0 1.7*** 0.6*** 1.3** 0.9 1.0
Vasorelaxant 0.7*** 1.1 1.3* 1.8*** 0.8*** 1.4** 0.9 0.9
Fibrate 0.9 0.9 1.1 0.9 0.3*** 0.2*** 0.8 0.8
Non-statin and ﬁbrate lipid-lowering
drugs
2.6*** 1.7*** 6.2*** 3.1*** 7.0*** 3.6*** 2.0*** 1.8***
Heparin 0.8* 1.0 0.6*** 0.9 0.8* 1.0 1.1 1.1
Oral anticoagulant 0.7*** 1.2 0.1*** 0.1*** 0.6*** 1.3* 1.2* 1.1
288 P. Tuppin et al.
Table 3 (Continued )
Beta-blocker Antiplatelet Statin ACE-I/ARB
OR ORa OR ORa OR ORa OR ORa
Comorbidity
Neoplasia 0.7*** 0.9 0.6*** 0.9 0.6*** 0.9 0.8** 0.8
Diabetes mellitus 0.9 1.3** 1.0 1.3* 0.9* 1.2* 1.8*** 1.8***
Renal disease 0.9 1.6 0.7 1.0 0.5*** 0.7 0.3*** 0.3***
Chronic obstructive pulmonary disease 0.2*** 0.3*** 0.9 1.1 0.7*** 0.9 1.1 1.1
Alzheimer’s disease 0.3*** 0.5* 0.5* 1.2 0.2*** 0.5* 0.7 1.1
Parkinson’s disease 0.4*** 0.8 0.6 1.0 0.3*** 0.5* 0.5** 0.6
Depression 0.8*** 1.3* 0.7** 1.2 0.6*** 1.2* 0.8* 1.0
Non-steroidal anti-inﬂammatory use 0.9* 1.0 1.1 1.0 0.9 0.9 1.2* 1.2
Chronic hepatic disease 0.7 0.7 0.5 0.6 0.8 0.8 0.6 0.6
Psychotic disorder 0.6*** 0.6*** 0.6*** 0.5** 0.6*** 0.6** 0.6*** 0.8
Full coverage for a LTD
LTD for coronary disease
Before MI hospitalization 1.5*** 1.4*** 2.1*** 1.5** 1.8*** 1.3** 1.3*** 1.3*
After MI hospitalization 3.4*** 2.0*** 6.6*** 3.5*** 5.3*** 2.7*** 1.6*** 1.5***
LTD for other cardiological disease
Before MI hospitalization 0.6*** 1.0 0.5*** 1.0 0.5*** 1.0 1.0 1.1
After MI hospitalization 0.9 1.0 0.7** 0.8 0.8 0.8 1.5*** 1.3*
No LTD 0.5*** 0.7*** 0.3*** 0.5*** 0.3*** 0.6*** 0.5*** 0.8**
*< 0.05; **< 0.01; ***< 0.001.
LDT: long-term disorder; OR: odds ratio; MI: myocardial infarction; ACE: angiotensin converting enzyme angiotensin-receptor-blocker
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a Adjusted for all factors in the table.
igniﬁcantly less chance of receiving the full combination
f recommended medications; prescription is lower for all
our classes of medications. One possible explanation could
e that very young patients do not perceive the importance
f taking several preventive medications on a regular basis.
his will certainly need further investigation.
Diabetic patients are at higher risk of an ischaemic event
fter an acute MI. In our study, and in contrast with other
eports [19], they had a higher level of use of combined
herapy and of each class independently; while the differ-
nce, compared with non-diabetic patients, did not reach
tatistical signiﬁcance before adjustment, it became highly
elevant after full adjustment (OR 1.5). This may be the
esult of the emphasis that has been placed recently on
he speciﬁcities and need for optimal care of the diabetic
opulation with coronary artery disease. The recent Euro
eart Survey programme conﬁrms the beneﬁts of the use of
ecommended therapy in diabetic patients [20].
The negative association between concomitant diseases
nd use of secondary prevention medications is hardly
urprising. The reasons for the under prescription range
rom possible contraindications (asthma and betablocking
gents) to reluctance vis-à-vis the prescription of additional
edications in patients already receiving a number of
on-cardiovascular drugs. In contrast, secondary prevention
edications are used more often in patients who undergo
yocardial revascularization by coronary angioplasty or
oronary artery bypass surgery. The positive impact of coro-
ary angioplasty had been noted previously [34]; data on
he inﬂuence of coronary bypass surgery are contradictory,
s combined secondary prevention therapy has previously
a
n
r
c
teen found to be lower in patients who have undergone
ypass surgery [27].
Finally, the positive association between visits to a car-
iologist and the prescription of recommended medications
s encouraging, and follows the process of implementing
cientiﬁc knowledge in the medical community: guidelines
re usually written by cardiology experts and are applied
nitially in academic institutions. The second step is their
issemination within the community of cardiology special-
sts, while the education of general practitioners and the
atients themselves comes as the ﬁnal steps. Conversely,
atients with multiple comorbidities are more likely to be
ospitalized in non-specialized centres, and comorbidities
ay therefore constitute confounding factors [22].
trengths and limitations
he strength and originality of this study are that it
as cross-linked several medicoadministrative databases,
hereby providing comprehensive hospitalization and medi-
al consumption data. Because the general health insurance
cheme covers 70% of the French population, our data are
ikely to be fairly representative of the level of care in
rance in 2006, though we cannot exclude that populations
overed by other health insurance systems might have been
reated differently. Access to reimbursement databases
llowed us to use data on medications for concomitant,
on-cardiovascular diseases as adjustment variables. The
eimbursement database is comprehensive for all medi-
ations purchased and reimbursed and, in contrast with
elephone or mail surveys, there are no non-responders.
Com
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Table 4 Factors associated with the use of evidence-based combination treatment six months after myocardial infarction in France.
OR p value OR adjusted for sex and age p value OR adjusteda p value CI
Male sex 1.9 < 0.0001 1.2 < 0.0001 1.2 0.002 1.1—1.3
Age (years)
≤ 44 1.0 1.0 1.0
45—54 1.3 < 0.001 1.3 < 0.001 1.3 0.006 1.1—1.5
55—64 1.1 0.11 1.1 0.10 1.2 0.016 1.0—1.5
65—74 1.0 0.71 1.0 0.95 1.2 0.01 1.0—1.5
75—84 0.5 < 0.0001 0.5 < 0.0001 0.8 < 0.01 0.7—0.9
≥ 85 0.2 < 0.0001 0.2 < 0.0001 0.4 < 0.0001 0.3—0.4
Full healthcare coverage for low earners 1.1 0.18 0.8 0.003 0.9 0.32 0.8—1.1
Six months prior to hospitalization
One or more outpatient cardiologist appointments 0.8 < 0.001 0.9 0.20 1.1 0.33 0.9—1.2
Admitted to cardiology unit for
Stent implantation 1.2 0.11 1.2 0.24 1.3 0.03 1.0—1.7
Other diagnoses 0.6 < 0.0001 0.7 < 0.0001 0.8 0.002 0.7—0.9
Admitted to other unit 0.6 < 0.0001 0.7 < 0.0001 0.9 0.03 0.8—1.0
Hospitalization for MI
Hospital type
University hospital 1.0 1.0 1.0
Private clinic 0.6 < 0.0001 0.6 < 0.0001 0.5 < 0.0001 0.5—0.6
Community hospital 0.5 < 0.0001 0.6 < 0.0001 0.7 < 0.0001 0.6—0.7
Annual MI admitted to hospital (2006)
≤ 49 1.0 1.0 1.0
50—99 1.3 < 0.001 1.2 0.08 1.1 0.52 0.9—1.3
100—299 2.0 < 0.0001 1.6 < 0.0001 1.3 < 0.01 1.1—1.5
≥ 300 2.7 < 0.0001 2.0 < 0.0001 1.3 < 0.001 1.1—1.6
Stent implantation 2.7 < 0.0001 2.1 < 0.0001 1.9 < 0.0001 1.7—2.0
Length of stay (weeks)
≤ 1 1.0 1.0 1.0
2 0.7 < 0.0001 0.9 0.02 0.9 0.23 0.8—1.0
3 0.4 < 0.0001 0.7 < 0.0001 0.8 0.01 0.6—1.0
≥ 4 0.3 < 0.0001 0.4 < 0.0001 0.5 < 0.0001 0.4—1.0
Six months after hospitalization
Admitted to cardiology unit for
Stent implantation 1.6 < 0.0001 1.5 < 0.0001 1.9 < 0.0001 1.6—2.1
Coronary bypass grafting 1.3 < 0.01 1.1 0.34 1.6 0.0001 1.3—2.0
Coronary disease 1.1 0.05 1.2 < 0.01 1.4 < 0.0001 1.2—1.6
Catheterization 1.0 0.58 0.8 0.02 1.1 0.46 0.9—1.3
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Table 4 (Continued )
OR p value OR adjusted for sex and age p value OR adjusteda p value CI
Other diagnosis 0.8 < 0.0001 0.9 0.0163 1.0 0.71 0.8—1.1
Admitted to other unit 0.7 < 0.0001 0.8 < 0.0001 0.9 0.07 0.8—1.0
One or more outpatient cardiologist appointments 1.4 < 0.0001 1.3 < 0.0001 1.2 < 0.0001 1.1—1.3
Associated medications
Non-thiazide 0.7 < 0.0001 1.0 0.34 1.5 < 0.0001 1.4—1.7
Thiazide 1.4 < 0.0001 1.6 < 0.0001 2.0 < 0.0001 1.7—2.4
Calcium channel blocker 0.4 < 0.0001 0.5 < 0.0001 0.4 < 0.0001 0.4—0.5
Cardiotonic steroid 0.3 < 0.0001 0.5 < 0.0001 0.7 0.05 0.4—1.0
Antiarrhythmia agent class III 0.4 < 0.0001 0.5 < 0.0001 0.5 < 0.0001 0.5—0.6
Nitrate 0.6 < 0.0001 0.9 0.04 1.0 0.51 0.9—1.2
Vasorelaxant 0.7 < 0.0001 0.9 0.03 1.0 0.73 0.9—1.2
Fibrate 0.6 < 0.001 0.5 < 0.0001 0.5 0.0001 0.4—0.7
Non-statin and ﬁbrate lipid-lowering drugs 2.6 < 0.0001 2.0 < 0.0001 1.8 < 0.0001 1.6—2.1
Heparin 0.7 < 0.0001 0.7 < 0.0001 0.9 0.14 0.7—1.0
Oral anticoagulant 0.5 < 0.0001 0.6 < 0.0001 0.7 < 0.0001 0.6—0.8
Comorbidity
Neoplasia 0.6 < 0.0001 0.7 < 0.0001 0.8 0.02 0.6—1.0
Diabetes mellitus 1.1 0.07 1.2 < 0.001 1.5 < 0.0001 1.3—1.7
Renal disease 0.4 < 0.0001 0.4 < 0.0001 0.5 0.001 0.3—0.8
Chronic obstructive pulmonary disease 0.4 < 0.0001 0.4 < 0.0001 0.5 < 0.0001 0.4—0.6
Alzheimer’s disease 0.2 < 0.0001 0.4 < 0.001 0.4 0.0007 0.2—0.7
Parkinson’s disease 0.3 < 0.0001 0.4 < 0.001 0.5 0.02 0.3—0.9
Depression 0.7 < 0.0001 0.8 < 0.01 1.0 0.75 0.9—1.2
Non-steroidal anti-inﬂammatory use 0.9 0.01 1.0 0.47 1.0 0.72 0.9—1.1
Chronic hepatic disease 0.8 0.28 0.6 0.05 0.7 0.25 0.4—1.3
Psychotic disorder 0.7 < 0.001 0.6 < 0.0001 0.7 0.02 0.6—1.0
Fully coverage for a long-term disorder (LTD)
LTD for coronary disease
Before MI hospitalization 1.4 < 0.0001 1.4 < 0.0001 1.3 < 0.001 1.1—1.6
After MI hospitalization 2.6 < 0.0001 2.0 < 0.0001 1.7 < 0.0001 1.5—1.9
LTD for other cardiological disease
Before MI hospitalization 0.6 < 0.0001 0.8 < 0.0001 1.1 0.34 0.9—1.2
After MI hospitalization 0.9 0.52 1.0 0.69 1.1 0.25 0.9—1.3
No LTD 0.5 < 0.0001 0.6 < 0.0001 0.8 0.009 0.7—0.9
OR: odds-ratio; CI 95%: conﬁdence interval; MI: myocardial infarction.
a Adjusted for all factors in the table.
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It does not take into account self-medication, rare in this
context, nor the fact that some patients might buy the
medications and not actually use (swallow) them; actual
use of the medications, however, is certainly more likely
when the medications have been purchased repeatedly than
when drug usage is accounted for on the sole basis of medi-
cal prescriptions by the doctors or self-declaration by the
patients. Assessment of medication consumption (mainly
three reimbursements over six months) was based on the
deﬁnitions used in pharmacovigilance and other studies, and
is an approximation of actual drug usage. Finally, the medi-
coadministrative nature of the databases does not permit
adjustment for certain speciﬁc clinical factors, such as those
specifying the extent or clinical severity of the disease. This
is not a problem with regard to the description of the use of
medications, but limits the capacity to determine correlates
of medication underuse. In medicoadministrative databases,
diagnosis and comorbidities can be misclassiﬁed. Neverthe-
less, hospital mortality of coronary heart disease is generally
estimated at 10%, as was found in our study. For comorbidi-
ties, diagnosis was strengthened by other data on speciﬁc
medication reimbursement of full coverage for a long-term
chronic disease.
Conclusions
The use of secondary prevention medications, including the
recommended quadruple therapy, in the months following
an acute MI appears rather satisfactory and has improved
in recent years. Under utilization of secondary prevention
therapy, however, remains a concern in several subsets of
patients, such as the very elderly or the younger age groups,
as it is for patients taken care of in less specialized centres.
For these speciﬁc populations in particular, a continuous
benchmarking process, such as has been implemented in
England and Wales with the MINAP project [10], would most
probably contribute to improved patient care. Finally, these
data appear encouraging with regard to the French health
insurance system, which provides a uniform quality of care,
independently of the patients’ socioeconomic status.
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